Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to investigate the dose-dependent bronchodilator effect and the safety of single
inhalation doses of BEA 2180 inhaled via Respimat® compared to placebo in patients with
stable Chronic Obstructive Pulmonary Disease (COPD)